ArticleCancer diagnosis & prognosis
Methionine Restriction Must Be Continuously Maintained to Selectively Inhibit Cancer Cells Co-cultured With Normal Cells.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Methionine addiction (Hoffman effect) is a fundamental and general cancer hallmark targetable by methionine restriction, using methionine-depleted media or diet, or recombinant methioninase (rMETase). Our previous studies showed differential sensitivity of HCT-116 colon-cancer cells and Hs27 normal fibroblasts to rMETase in co-culture. The present study aimed to demonstrate the rescue conditions of cancer cells by methionine replenishment in the co-cultures of HCT-116 and Hs27 cells after rMETase treatment. Materials and Methods: Equal numbers of HCT-116 colon-cancer cells and Hs27 normal fibroblasts were co-cultured in 6-well plates in Dulbecco's modified Eagle's medium (DMEM). Two days after seeding, co-cultures were treated with rMETase at the HCT-116 IC50 (0.46 U/ml) or left untreated as controls. Growth of each cell type in co-culture was evaluated by phase-contrast microscopy on days 2, 4, 6, 8, 10, and 12 after treatment to assess the response to rMETase. On day 12, the existing medium in all wells was replaced with fresh DMEM containing methionine (methionine replenishment). Regrowth of HCT-116 and Hs27 was then assessed by phase-contrast microscopy 3, 6, and 9 days later. Results: In the untreated control group, HCT-116 cancer cells rapidly proliferated, and progressively overtook the Hs27 fibroblasts and predominated by day 12. In the rMETase-treated group, viable HCT-116 cells progressively decreased and were almost undetectable by day 12, whereas Hs27 cells remained viable throughout the observation period. After day-12 replenishment of methionine, previously rMETase-treated co-cultures showed reappearance of viable HCT-116 cells by day 3 and dominance over Hs27 cells by day 9. Conclusion: Continuous treatment with rMETase is necessary to maintain inhibition of cancer cells and normal-cell dominance in co-culture with cancer cells. These results have clinical implications indicating that methionine restriction must be continually maintained to inhibit cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.